Hengrui Pharmaceuticals: Irinotecan Hydrochloride Liposome Injection (II) Clinical Trial Approved

MetaMuskRat · 2026-03-13T09:41:19+00:00

Hengrui Pharmaceuticals announced that its subsidiary has obtained clinical trial approval for liposomal irinotecan hydrochloride injection and will conduct relevant trials. Additionally, the company's marketing application for semaglutide injection has been accepted for review, which is used to improve blood glucose control in patients with type 2 diabetes.

MetaMuskRat

2026-03-13 09:41:19

Abstract generation in progress

People’s Financial News, March 13 — Hengrui Medicine (600276) announced on March 13 that recently, its subsidiary Shanghai Hengrui Medicine Co., Ltd. received the “Drug Clinical Trial Approval Notice” from the National Medical Products Administration (NMPA) for Liposomal Itraconazole Hydrochloride Injection (II), and clinical trials will be conducted soon. According to research, the global total sales of Itraconazole-related formulations in 2024 are approximately $373 million. As of now, the total R&D investment in the Liposomal Itraconazole Hydrochloride Injection project is about 425 million yuan (unaudited). On the same day, the company announced that it recently received the “Acceptance Notice” from the NMPA for its application for marketing approval of Shude Insulin Noliglutide Injection. This product is suitable for adult patients with type 2 diabetes who have poor blood sugar control, and it is used in combination with other oral hypoglycemic drugs to improve blood sugar management based on diet and exercise.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.